Amylin's Bydureon endures rejection; finally embraced by FDA
This article was originally published in Scrip
Executive Summary
As if it had 1980s disco diva Gloria Gaynor singing it to the finish line, Amylin's Type II diabetes drug Bydureon (exenatide extended-release for injectable suspension) – twice rejected by the US FDA and recently separated from longtime partner Lilly – indeed survived, and finally won US approval on 27 January.